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Available online 2 November 2013Abstract Gene therapy mediated by bone marrow-derived hematopoietic stem cells (BM-HSC) has been widely used in
treating genetic deficiencies in both pre-clinical and clinical settings. Using mitotically inactive cell-targeting lentivirus with
separate promoters for our gene of interest (the murine MHC class II (MHCII) chaperone, invariant chain (Ii)) and a GFP reporter,
we monitored the expression and function of introduced Ii in various types of professional antigen presenting cells (B cells,
macrophages and DC) from different organs (spleen, pancreatic lymph nodes (PLN), BM and blood). Ii and GFP were detected. Ii
levels correlated with GFP levels only in macrophages and monocytes from spleen, monocytes from PLN and macrophage
precursors from blood. By cell type, Ii levels in PLN cells were more similar to those in spleen cells than to those in blood or BM
cells. Functionally, Ii expressed in PLN or spleen had more effect on MHCII abundance than Ii expressed in BM or blood. The
results have implications for analysis of the outcomes of gene therapy when both therapeutic and reporter genes are
introduced. The findings also have implications for understanding the development of immune molecule function.
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Open access unIntroduction
Hematopoietic stem cells (HSC) are multi-potent cells
responsible for the development, maintenance, and
regeneration of all formed blood elements, including
those of the immune system. Bone marrow (BM) is the
main source of HSC for experiments in mice, whereas in
humans, HSC also are isolated from mobilized peripheral
blood (MPB) or cord blood. Autologous BM or MPB are more
useful than allogeneic sources in human gene therapy
trials (Woods et al., 2002). The unique self-renewal and
differentiation properties of HSC guarantee that the
transgenes expressed in a small number of HSC result
in long-term correction of much larger numbers of mature
progeny, making HSC promising target cells for therapy of
genetic anemias, immunodeficiencies and metabolic dis-
eases (Aiuti et al., 2013; Bank, 2003; Barrette et al., 2000;
Biffi et al., 2013; Wanisch and Yanez-Munoz, 2009). HSC
transplantation is also a possible strategy for treatingder the CC BY-NC-ND license.
210 N. Wang et al.leukemia, non-hematopoietic tumors and autoimmune
diseases as well as in induction of tolerance for solid
organ transplants (Shizuru et al., 2005).
HIV-based lentivirus transduces post-mitotic and
non-dividing cells, including HSC, by active transport
through the nucleopore, independent of nuclear enve-
lope breakdown during cell division (Buchschacher and
Wong-Staal, 2000; Chicurel, 2000; Frimpong and Spector,
2000). Its other characteristics, including the capacity to
integrate into the host chromosome with subsequent
long-term transgene expression, large coding capability,
relatively high transduction efficiency and low immuno-
genicity, further support its use as a delivery vector in
BM-HSC mediated gene therapy (Hu et al., 2011). Single
transgene (GFP reporter or therapeutic exogenous gene)
expression in the progeny of lentivirus-transduced HSC
has been studied widely. GFP expression was observed in
BM and spleen of immunodeficient murine recipients
reconstituted with human CD34+ HSC from G-CSF—
mobilized peripheral blood or cord blood that were
transduced with pan- or cell type-specific promoter
containing lentivirus (Cui et al., 2002; Kahn et al.,
2004; Verhoeyen et al., 2005). Similarly, expression of
either the GFP reporter or the therapeutic gene alone
was observed in various organs (BM, thymus, spleen,
lymph nodes, blood) in normal mice, immunodeficient
mice or (the corresponding) single gene deficient mice,
after lentivirus-transduced HSC transplant (Astrakhan et
al., 2012; Heckl et al., 2011; Levasseur et al., 2003;
Marodon et al., 2003; Mostoslavsky et al., 2006;
Perumbeti et al., 2009; Zhang et al., 2007). Sustained
GFP expression was detected in blood and BM in
nonhuman primates up to 4 y post transplantation with
lentivirus-transduced HSC (Kim et al., 2009; Trobridge et
al., 2008). In two X-linked adrenoleukodystrophy (ADL)
patients who lack ADL protein, this protein was detected
in 9–14% of various blood cells and in 17–20% BM CD34+
cells up to 30 m after transplant with the HSC transduced
by lentivirus encoding ALD protein. Accordingly, progres-
sive cerebral demyelination was attenuated (Cartier et
al., 2009). More recently, effective therapeutic trans-
gene expression mediated by lentivirus-transduced HSC
was reported in patients with metachromatic leukodys-
trophy or Wiskott–Aldrich syndrome (Aiuti et al., 2013;
Biffi et al., 2013).
Using a lentiviral vector containing two separate
promoters for two transgenes (i.e. EF1a for our gene of
interest, murine invariant chain (Ii), and MSCV for the
reporter gene-GFP), we monitored Ii and GFP levels in
various antigen presenting cell (APC) types from differ-
ent organs in NOD mouse recipients up to 8 m post
BM-HSC transplantation. We analyzed the correlation
between Ii and GFP levels in different organs (blood, BM,
pancreatic lymph nodes (PLN) and spleen) and the
correlation between Ii levels in PLN and Ii levels in
other organs. We also examined the function of the
introduced Ii. The results provide information relevant
for analyses of in vivo expression of two transgenes
introduced together. They also suggest that the expres-
sion level and function of certain immune molecules may
develop along with maturation of immune cells, such as
APC.Materials and methods
Lentiviral vector and viral packaging
cDNA of 3xflag-tagged WT or mutant Ii (M98A) (Rinderknecht
et al., 2010) was cloned into the multiple cloning site driven
by an MSCV promoter in a dual-promoter lentiviral vector,
containing GFP driven by an EF1a promoter (System Bioscience,
Mountain view, CA). The positions of GFP and Ii were then
switched so that EF1a and MSCV become promoters for Ii and
GFP respectively (Wang et al., 2013).
Lentivirus was produced in 293T cells by calcium phosphate
precipitation of the abovementioned dual-promoter vector,
envelop plasmid VSV and packaging plasmid PAX2. Culture
media were replaced 8 h post-transfection and lentivirus
containing supernatants then were harvested 24 h later.
Supernatants were filtered, precipitated and concentrated
with PEG-it Virus Precipitation Solution (System Bioscience),
according to the manufacturer's instructions. Lentiviral titer
was determined by measuring % of GFP+ 293T cells after
transduction with time-diluted viruses and confirmed by
quantitative real time PCR to determine the vector integration
copy number into the host chromosomes (Kutner et al., 2009).
BM-HSC isolation, transduction and transplantation
ckit+ BM cells from 3 to 5 m NOD mice (CD45.1+, 50% of which
had high blood glucose, i.e. N250 mg/dl) were enriched by
CD117 microbeads (Miltenyi Biotec, Auburn, CA) and stained
with monoclonal antibodies for linage (Lin) markers (CD3, CD4,
CD8, B220, Gr1, Mac1, Ter119) and stem/progenitor cell
markers (ckit and Sca-l) then sorted for HSC (cKit+Sca1hiLin−)
using FACS-Aria (BD bioscience, San Jose, CA) (Rajasekaran et
al., 2013). HSC were transduced with lentiviruses encoding wt
or mutant Ii at MOI = 80 for 8 h in the presence of 8 μg/ml
polybrene (Lu et al., 2011) after pre-activation with 100 ng/ml
SCF and 100 ng/ml TPO overnight. 10,000 transduced HSC/
mouse were transplanted by tail vein injection into 8–12w
NOD recipients (CD45.2+, with normal blood glucose) that
had been lethally irradiated at 980 cGy. Chimerism (%CD45.1
vs. %CD45.2) and levels of GFP and Ii were detected by FACS up
to 8 m post-transplantation. Abs and cytokines were purchased
from eBioscience (San Diego, CA) and Peptrotech (Rocky Hill,
NJ) respectively. NOD mice were bred and housed in the
Stanford Veterinary Service Center under the approval of
Administrative Panel for Laboratory Animal Care.
Flow cytometry analyses
For in vivo GFP and Ii expression, BM, blood, pancreatic lymph
nodes (PLN) and spleens were harvested from lentivirus-
transduced HSC recipients. After RBC lysis, 1E6 cells were
stained with Abs recognizing key markers of different
compartments, i.e. B220+ for B cells, CD11b+ for myeloid
cells, CD11b+F4/80+ for macrophages or macrophage pre-
cursors (ma-precursors in blood), CD11b+F4/80− for mono-
cytes, CD11c+ for dendritic cells (DC). GFP expression was
measured in different compartments. 2E6 cells stained first
with compartment markers were then fixed, permeabilized
and stained with Abs against Flag (i.e. biotin-labeled anti-Flag
Ab (Sigma-Aldrich, St. Louis, MO) followed by PO-conjugated
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duced Ii level. Data from stained cells were collected on a LSR II
flow cytometer (BD Bioscience) and analyzed with FlowJo
software (Tree Star Inc., Ashland, OR). Live white blood cells
were gated by FSC and SSC to remove dead cells, red blood cell
fragments and platelets. The threshold of positivity for each
cell type from each organ was set based on a sample from the
same cell type in the corresponding organ of an untransplanted
NOD mouse as the negative control (data not shown). In BM
samples, immature progenitor and stem cells (CD117+) were
gated out before analysis of Ii and GFP levels in differentiated
APC. Abs were purchased from Biolegend (San Diego, CA),
unless otherwise mentioned.
Ii functional analysis
To assess the function of introduced Ii, flow cytometry was
used to measure the levels (histogram and median MFI) of
I-Ag7, the MHC class II allele expressed by NOD mice. I-Ag7
levels were compared between the Flag+ (representing cells
expressing exogenous Ii) and Flag− populations (representing
non-expressing, likely non-transduced, cells) in recipients of
BM-HSC transduced by WT or mutant Ii containing lentivi-
ruses. The Flag expression levels represented by their median
MFI values of those two populations were also analyzed. The
ratios of median MFI of I-Ag7 to median MFI of Flag were
compared between WT and M98A recipients.
Statistical analyses
Data from 12 wt and 11 mutant Ii recipients from 3 separate
transplantations were combined; GFP and Ii expression levels
were not significantly different in wt vs. mutant Ii recipients
(not shown). Correlations between Ii and GFP levels in each APC
type fromeach organ aswell as the association between Ii levels
in pancreatic lymph nodes (PLN) and spleen, blood and BMwere
shown by the regression line and analyzed by the nonparametric
Spearman rank correlation test. Comparison of I-Ag7 enhance-
ment (median MFI) in wt or mutant Ii transduced population
(Flag+) vs. non-transduced population (Flag−) was calculated by
2-tailed paired t test. I-Ag7 levels of wt andmutant Ii transduced
populations were compared using a non-paired t test. Median
MFI of I-Ag7 in transduced population was normalized to
non-transduced population set to 1. These statistical analyses
were also applied for evaluating Flag (introduced Ii) level
(relative median MFI, normalized to Flag− population as 1) in
Ii transduced vs. non-transduced population. I-Ag7/Flag ratios
(using relative median MFI) in Flag+ population were compared
between wt andmutant Ii recipients using non-paired t test. All
statistical analyses were done with Prism software (GraphPad
Software, Inc., La Jolla, CA). P b 0.05 was considered statisti-
cally significant.
Results
Ii and GFP are detected in various types of APC from
different organs
Using qPCR and FACS, we previously observed expression of GFP
and Ii in 293T cells transduced with dual promoter lentiviralconstructs containing wt or mutant (M98A) Ii and GFP (Wang et
al., 2013). To evaluate the in vivo expression level of these
transgenes using the same constructs (see Materials), trans-
duced NOD BM-HSC were transplanted into lethally irradiated
NODmice. Blood, BM, spleen and pancreatic lymph nodes (PLN)
were harvested up to 8 m post-transplantation. As our gene of
interest, murine Ii, a chaperone for the assembly and transport
of MHC class II, is mainly expressed and functional in antigen
presenting cells (APC), we focused on monitoring Ii levels in
professional APC (B cells, macrophages and dendritic cells
(DC)). Cell types initially were defined with commonly used
markers, i.e. B220 for B cells, CD11b for macrophages/
monocytes and CD11c for DC. Ii levels in monocytes, the
immature or pre-activated form of macrophages, were also
monitored. In addition, monocytes can develop into DC (Gordon
and Taylor, 2005; Sunderkotter et al., 2004). A small subset of
blood monocytes expressing macrophage marker F4/80 (Nikolic
et al., 2005) were assessed here, as macrophage-precursors. As
shown by one representative mouse for each type of recipient,
i.e. wt and M98A, in Fig. 1, an intermediate level of GFP and
usually a lower level of Ii (represented by the expression of the
Flag tag) were observed in all types of APC from all 4 organs.
In peripheral organs, such as PLN, spleen and blood, macro-
phages expressed the highest level of transgene followed by
DC/monocytes and B cells. The trend is more obvious in Ii
expression than in GFP expression. In BM, however, this
macrophage N DC N B cells trend was lost. No significant
difference was observed between wt and M98A recipients in
either GFP or Ii expression in any APC type from any organ,
arguing that the Ii point mutation did not affect either Ii or GFP
expression.GFP and Ii levels correlate in myeloid
compartments onlyWe chose to express GFP as a reporter gene together with Ii
for two reasons: 1) GFP is easier than Ii to detect by FACS, as
the latter requires cell permeabilization; 2) GFP can be used
as a marker for sorting live cells. Among the various
lentiviral vectors expressing the two transgenes together,
those with a separating sequence (IRES or T2A) under a
single promoter either have imbalance in expression levels
of the two genes (i.e. IRES) (Yu et al., 2003) or the particular
promoter did not work effectively in the murine HSC
environment; (T2A under the MSCV promoter failed to
induce in vivo GFP and Ii expression, data not shown).
However, interference between the two separate pro-
moters also may affect the expression levels of the
corresponding genes (Curtin et al., 2008). To investigate
whether GFP, as a reporter, reflects the expression of our
gene of interest (Ii), we tested the correlation between the
two proteins in various APC types from different organs. As
shown in Fig. 2, the correlation between Ii and GFP levels
was significant only in myeloid compartments (i.e. splenic
and PLN monocytes as well as blood macrophage-
precursors, P b 0.05). The correlation of Ii and GFP in
splenic macrophages and BM B cells approached, but did not
reach significance, at P b 0.05. Thus, only in some subsets
of myeloid cells in the periphery, GFP levels paralleled Ii
levels.
Blood
Spleen
BM
PLN
A) B)
C) D)
Figure 1 Representative transgene expression in various types of APC from different organs. Organs from Ii wt and M98A Ii
recipients were harvested, stained with proper Abs and analyzed by FACS. Panels A, B, C and D show samples from spleens, PLN, blood
and BM, respectively, of a representative animal from each group. For each panel, rows 1 and 2 show samples from the wt recipient
and rows 3 and 4 show samples from the M98A recipient. Rows 1 and 3 show GFP expression (as % of total donor cells) and rows 2 and 4
show Ii levels (as % of total donor cells). The Ii level is represented by the level of Flag. The threshold of positivity in each cell type
from each organ was set using a sample from the corresponding cell type in the corresponding organ of an untransplanted NOD mouse
as the negative control (data not shown). Data shown are representative of three independent transplantation experiments.
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other organs
Transgene expression level is important for evaluation of the
outcome of gene therapy. Blood and BM samples commonlyare used for detecting transgene expression in non-human
primates and patients (Aiuti et al., 2013; Biffi et al., 2013;
Cartier et al., 2009; Kim et al., 2009; Trobridge et al., 2008).
As GFP level generally did not reflect Ii level (Fig. 2), we did
not compare GFP levels in additional analyses. Rather, to
213Expression of transgene in various organs after BM-HSC transplantationdetermine if transgene expression in blood or BM reflected
transgene levels in other target organs, we analyzed the
correlations between Ii levels in different organs. As PLN
are critical sites for mediating the pathogenesis of type I
diabetes in NOD mice, we compared Ii levels in PLN to those
in blood or BM. Spleen also acts as a secondary immune
organ, so we tested the relative expression of Ii in PLN
compared to spleen. Ii levels in myeloid cells (monocytes
and macrophages) and DC from spleen correlated with
those from PLN (P b 0.05). Similarly, in blood, Ii levels in
macrophage precursors and DC significantly correlated with
those in PLN. The correlation between Ii levels of splenic
and PLN B cells showed a trend, but was not significant
(Fig. 3A). Levels of Ii in circulating B cells and monocytes did
not correlate with levels in PLN (Fig. 3B). No correlation
with PLN expression of Ii was observed in BM B cells, myeloid
cells or DC (Fig. 3C). Together, these data argue that, for Ii
as a transgene, expression levels in circulating macrophage-
precursors and DC correlate with expression in these cell types
in secondary immune organs, but this is not the case for
monocytes and B cells.
It was possible that one contributor to the lack of
correlation we observed was that the markers we used
collected heterogeneous populations that differed in make-up
in different organs. To explore this possibility, we analyzed the
percentage of APC bearing other markers that are found within
the single marker populations we initially analyzed (Fig. 4A,
n = 23 mice). B cells represented by B220+ contained very
few CD11b+ and CD11c+ cells, i.e. b3% in all the organs. DC
represented by CD11c+ expressed certain amount of B220 and
CD11b, presumably on plasmacytoid DC (pDC) and myeloid DC
(mDC) respectively. As it is widely accepted that both subsets
belong to DC (Ziegler-Heitbrock et al., 2010), we did not
distinguish those two subsets in the DC population. However, a
potential concern is the possible overlap between myeloid DC
and inflammatory myeloid cells. Macrophages/monocytes
can express CD11c under inflammatory conditions without
converting into DC (Drutman et al., 2012; Wentworth et al.,
2010). T1D in NOD mice results from inflammatory insulitis
(Kaminitz et al., 2013), is exacerbated by intestinal inflamma-
tion (Alam et al., 2010) and is blocked by anti-inflammatory
therapy (Xue et al., 2012), so it was likely that inflammatory
myeloid cells are present in these mice. However, we noted
that splenic mDC and inflammatory macrophages/monocytes
can be distinguished by the differences in the fluorescent
intensity of CD11b and CD11c, i.e. CD11chighCD11bint (with
average MFI of CD11c and CD11b as 4840 and 3079 respective-
ly) for mDC versus CD11bhighCD11cint (with average MFI of
CD11b and CD11c as 7578 and 1089 respectively) for inflam-
matory macrophages/monocytes (data not shown). Thus, we
included only CD11cint cells in the myeloid population and
excluded mDC. Of note, inflammatory myeloid cells and
myeloid DC can be more accurately separated by Ly6C level
(Drutman et al., 2012).
In addition, we found that in CD11b+ cells from spleen and
PLN, N5% of cells are also B220+, whereas these double
positive cells are present in blood and BM at a negligible
frequency. CD11b+B220+ cells have been found in other
autoimmune models, such as experimental allergic enceph-
alomyelitis and MRL-Faslpr mice (Davoust et al., 2006; Iwata et
al., 2010); we speculate that they may play a pro-inflammatory
role in those settings. As the function of CD11b+B220+cells in diabetes has not been fully elucidated, we used
CD11b+B220− cells to re-analyze the correlation between
GFP and Ii (Flag) expression and the Ii (Flag) expression in
different organs (Figs. 4B,C). Compared to our results using
total CD11b+ cells (Fig. 2), the correlation between GFP and
Flag slightly increased using CD11b+ B220− cells in spleen and
PLN (Fig. 4B). As GFP in splenic and PLN B220+ cells correlated
less well with Flag than inmacrophages andmonocytes (Figs. 2A
and B), it is not surprising that analysis of CD11b+B220− cells
enhances GFP-Flag correlation. Re-analysis of correlations in Ii
expression between different organs using CD11b+B220− cells
shows no statistically significant differences compared to
original analysis using CD11b+ cells, except for the correlation
between macrophages in PLN and blood; this correlation was
substantially reduced, with the P value changing from 0.0176 to
0.0598 (compared Fig. 3 with Fig. 4C).Introduced Ii was more functional in PLN and spleen
than in blood and BM
A key aim of gene therapy is correction of host genetic
deficiencies by functional transgene(s). To test the function
of introduced Ii, the level of I-Ag7, the MHC class II allele
expressed by NOD mice, was measured in various APC cell
types from different organs. I-Ag7, like its human counter-
part DQ8, has low affinity for the core class II binding region
of Ii (AA 83–107) (Rinderknecht et al., 2010) and is tightly
linked to susceptibility to type I diabetes (Hausmann et al.,
1999). Point mutation of Ii at M98A significantly increases
the affinity between Ii and I-Ag7, thereby enhancing the
abundance of I-Ag7 (Rinderknecht et al., 2010).
Similar to our previous in vitro data, we saw significant
enhancement of I-Ag7 in all APC cell types expressing
introduced M98A Ii genes in PLN (Fig. 5, the third row and
Fig. 6B). More remarkable I-Ag7 elevation by M98A was
observed in splenic APC (B cells, monocytes, macrophages
and DC, Fig. 5, the first row and Fig. 6A) compared with the
same cells in PLN. Specifically, average enhancements of
1.27, 7.3, 6.51, 4.97 fold in median MFI of I-Ag7 by M98A
were observed in transduced-splenic B cells, macrophages,
monocytes and DC respectively, compared to untransduced
populations set to 1 (Fig. 6A). Although the relative order by
cell type was similar, smaller increases in the M98A-induced
I-Ag7 levels were seen in transduced-B cells, macrophages,
monocytes and DC from PLN: 0.33, 2.69, 1.04, and 1.26 fold
enhancements, respectively (Fig. 6B). We also found that wt
Ii increased I-Ag7 levels in PLN and spleen, generally to a
smaller degree than M98A, except in PLN monocytes and DC
(Fig. 5 the 2nd and 4th rows as well as Figs. 6A and B).
Specifically, in spleen cells, average enhancements of I-Ag7
median MFI of 0.64, 4.14, 1.47 and 2.66 fold were observed
in wt Ii transduced B cells, macrophages, monocytes and DC
respectively; in PLN, 0.16, 2.16, 1.86 and 1.57 fold increases
in I-Ag7 median MFI were detected in the corresponding APC
cell types (Figs. 6A and B). Although the differences in I-Ag7
expression driven by M98A compared to wt Ii were only
statistically significant in splenic B cells, the trend that M98A
enhanced I-Ag7 to higher level than wt was seen in other cell
types (Figs. 6A–B).
To examine the possibility that the enhanced functional
effect of M98A compared to wt (Fig. 5 rows 1–4 and Figs. 6A,
Figure 2 Correlation between GFP and Ii expression in various APC types from different organs. Samples from A. spleen; B. PLN; C.
blood; and D. BM demonstrate the relationship between GFP and Ii in B cells, monocytes/macrophages (in blood, macrophages are
macrophage precursors whereas in BM, macrophages and precursors are combined into myeloid cells) and DC. The correlations are
represented by the regression lines and analyzed by the nonparametric Spearman rank correlation test. r and P levels from the
Spearman test are shown for each chart on every panel. Data are from combined wt (n = 12) and M98A (n = 11) Ii recipients from
three independent transplantation experiments.
214 N. Wang et al.B) is due to the higher expression of M98A Ii versus wt Ii, we
measured level of introduced Ii, represented by Flag tag
expression, in wt vs. M98A recipients. As shown in Figs. 6E
and F, all transduced populations (i.e. Flag+ population,
compared to background on Flag− cells set to 1) expressed
significant levels of Flag over background. Flag levels in M98A
and wt recipients were very similar, the only difference being
between the M98A and wt Flag MFI in splenic macrophages
(3.289 ± 0.1692 in M98A vs. 2.743 ± 0.1210 in wt; P = 0.0146).
When we normalized the change in I-Ag7 levels for changes
in levels of Ii (using median Flag MFI), the effects of M98A
compared to wt Ii remained. In splenic B cells, macrophages,
monocytes and DC, the average I-Ag7/Flag values in M98A were
0.67, 2.6, 2.47 and 1.93 vs. 0.46, 2.27, 0.89 and 1.34 in wt.
Notably, the difference between M98A and wt effects in splenic
B cells remained statistically significant (P = 0.0406). In
corresponding cell types in PLN, the average I-Ag7/Flag values
in M98A were 0.45, 1.34, 0.92 and 0.74 vs. 0.39, 0.92, 1.24 and0.74 in wt. These results demonstrated that the enhanced
functional effects of M98A than wt were not due to increased Ii
expression (compare Figs. 6I & J vs. 6A & B).
The increase in I-Ag7 was smaller in BM and blood, compared
to spleen and PLN. In blood, the enhancing effect of Ii on class II
levels could be only seen in the macrophage-precursors (Fig. 5
rows 5 and 6, Fig. 6C). In BM, although statistical significance
was reached in more cell types, the increases were small
compared to those in PLN and spleen (Fig. 5 rows 7 and 8,
Fig. 6D). For example, the average enhancement of median
MFI of I-Ag7 in BM B cells, myeloid cells and DC was 0.09, 0.35
and 0.53 in M98A recipients and 0.07, 0.28 and 0.57 in wt
recipients (Fig. 6D). These results suggest that the function
of transgenically encoded Ii is influenced by the maturation
or activation state of the expressing cells in different locations.
No differences of Flag level between wt vs. M98A recipients
were observed in any APC cell types from blood or BM (Figs. 6G
and H). Even after normalization for Flag level, no significant
Figure 3 Correlation between Ii level in PLN and its levels in other organs. Ii expression in different APC cell types was compared
between PLN and spleen (panel A); PLN and blood (panel B); and PLN and BM (panel C, PLN monocytes and macrophages were
combined into myeloid cells). The regression lines were drawn, and the associations were tested by the Spearman test, as described
in Fig. 2. Data are from combined wt (n = 12) and M98A (n = 11) Ii recipients from three independent transplantation experiments.
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levels in all APC types from both blood and BM (Figs. 6K–L).Discussion
Using a dual-promoter lentivirus-transduced BM-HSC trans-
plantation model, we report here that both transgenes
(i.e. murine invariant chain (Ii) and the GFP reporter) can be
detected in various APC cell types from different organs
(Fig. 1). Thus, this lentiviral vector using two ubiquitous
promoters – the housekeeping Elongation Factor 1a (EF1a)
for Ii and Murine Stem Cell Virus (MSCV) for GFP – is efficient in
expressing the two transgenes together. However, imbalanced
expression of Ii and GFP was observed, with higher expression
of GFP than Ii in general and with correlation of GFP and Ii only
in monocytes/macrophages (Figs. 1 and 2). This imbalance may
be due to vector rearrangements and/or deletions, epigenetic
modification(s) or competition between promoters or en-
hancers for factors or competition for ribosomal association
(Curtin et al., 2008). Although the MSCV promoter is functionalin human HSC (Choi et al., 2001) and has been optimized in
murine embryonic stem cells with additional CPG mutations
at LTR region (Swindle et al., 2004), we found that it may
be specifically inhibited in the murine HSC environment both
in vivo and in vitro (Wang et al., 2013). On the other hand, EF1a
induced the highest transgene expression in human HSC
(in vitro) and their progeny cells (in vivo) among tested
promoters, including MSCV (Sirven et al., 2001; Woods et
al., 2002). Even with the better performing promoter EF1a
to drive Ii expression, we still observed lower levels of Ii than
of GFP encoded by the commercially optimized codons (Figs. 1
and 2). Thus, further improvement of expression of the gene of
interest by optimization of the vector and/or gene codons (Ellis,
2005; Moreno-Carranza et al., 2009) or by using a cell-specific
promoter (Cui et al., 2002) likely is warranted. As we only
observed the correlation between GFP and Ii in monocytes/
macrophages and there are technical difficulties detecting the
GFP+Ii+ population (i.e. Ii detection requires permeabilization,
whereas this procedure bleaches the fluorescence of GFP), the
use of GFP as a pan-representative for Ii should be done with
caution in this setting.
Figure 4 Analysis of CD11b+B220− cells. A. Percentage of cells bearing other APC markers. Data summarized from all 23 mice and
shown as mean ± SD. B. GFP-Flag correlation analysis in spleen and PLN macrophages and monocytes after removal of B220+ subset
from CD11b+ population. C. The association of Flag expression in PLN and other organs in CD11b+B220− population. No statistical
difference between wt and M98A recipients for any sub-population from any cell type was observed (data not shown), so the two were
combined. Correlations were tested by the Spearman test, as described in Fig. 2.
216 N. Wang et al.We also observed the highest levels of Ii and GFP
expression in macrophages, intermediate levels in DC, and
lowest expression in B cells from blood, spleen and PLN (Fig. 1).
The trend is not observed in BM. The higher level of transgene
expression in myeloid compared to lymphoid compartments has
been reported (Amsellem et al., 2002; Mostoslavsky et al.,
2005). The same trend was observed in progeny derived from
HSC transduced with oncoretrovirus (Klug et al., 2000). Possible
mechanisms underlying lower transgene expression in B cells
include chromatin remodeling accompanying B cell commit-
ment, the absence of positively acting transcription factors or
the presence of silencing factors, and/or higher levels of DNMT3
activity in lymphoid cells compared tomyeloid cells (Klug et al.,
2000). These factors all contribute to silencing of transgene
expression at the transcriptional level. It also is possible that
the EF1a promoter works better in myeloid than in lymphoid
compartments. As DC include both myeloid and lymphoid
subsets (Martin et al., 2000), the transgene level is expected to
be intermediate among the three cell types.Figure 5 Functional analysis of introduced Ii. I-Ag7 levels in exogen
non-expressing populations (gray line) were compared in spleen (rows 1
and 8) from one wt Ii containing lentivirus-transduced mouse (rows wi
numbers) 5 m post-transplantation. Data shown are representative of tBlood and BM are the most common samples collected for
detecting transgene expression in mice, nonhuman primates
and humans after administration of HSC-mediated gene
therapy. This is useful for some therapeutic transgenes carried
by blood cells (Aiuti et al., 2013; Biffi et al., 2013; Cartier et al.,
2009; Kim et al., 2009; Sirven et al., 2001; Trobridge et al.,
2008). However, the expression of therapeutic genes can be
substantially lower in target organs, such as the lung, compared
to blood (Aguilar et al., 2009). In addition, the expression of
certain immune molecules, like MHC class I molecules, derived
from lentivirus-transduced HSC were only transiently detected
cells at the protein level in peripheral blood, although their
mRNAs were consistently expressed (Zhang et al., 2005). Lower
levels of GFP driven by EF1a or an APC-specific promoter were
observed in spleen compared to BM (Cui et al., 2002). Here, we
did not observe any correlation between Ii expression levels
in BM and PLN in B cells, myeloid cells and DC. However,
a confounding variable is that the markers we used allow
inclusion of cells at different development stages. For example,ous Ii-expressing (represented by Flag expression, black line) vs.
and 2); PLN (rows 3 and 4); blood (BLD, rows 5 and 6) and BM (rows 7
th even numbers) and one M98A-transduced mouse (rows with odd
hree independent transplantation experiments.
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Figure 6 Relative median MFI of I-Ag7, Flag and I-Ag7/Flag in exogenous Ii-transduced vs. non-transduced populations. Relative
median MFI of I-Ag7 in Ii-transduced vs. non-transduced populations from various APC cell types were compared in spleen (A); PLN (B);
blood (C); and BM (D). Panels A-D: Median MFI of transduced cells was normalized to that of non-transduced cells set to 1.
Comparisons between relative I-Ag7 median MFI in transduced population and non-transduced population in HSC recipients transduced
with each lentivirus (i.e. wt or M98A) were analyzed by the paired t test. Comparisons between I-Ag7 level of wt and M98A derived
from same cell (marker-defined) population and organ were analyzed by the non-paired t test due to different numbers of wt vs. M98A
recipients. Only those differences that reached P b 0.05 are shown. The differences between transduced vs. non-transduced populations in
M98A and wt recipients are represented by bold lines and dashed lines, respectively. The difference between wt and M98A recipients from
same source is shown by the dotted line. Panels E–H, relative median MFI of Flag in non-transduced population (Flag−, set to 1) and
transduced population (Flag+, normalized to Flag−) from different organs (E, F, G, H for spleen, PLN, blood and BM respectively) harvested
fromwt or M98A recipients were compared, using paired or non-paired t test as in panels A–D. Panels I–L, the ratios of relativemedianMFI of
I-Ag7 to relativemedian MFI of Flag in the transduced population (Flag+, normalized to Flag−which was set to 1) from different organs (I, J, K,
L for spleen, PLN, blood and BM respectively) of wt or M98A recipients were compared using non-paired t test. Data combined wt (n =
12) and M98A (n = 11) Ii recipients from three independent transplantation experiments.
218 N. Wang et al.B220+ cells in BM contain 4 stages of premature subsets before
mature B cells (Nagasawa, 2006), whereas B220+ cells in PLN
and spleen are mostly mature B cells. This issue needs to
be considered, especially when analyzing BM. Blood Ii level
correlated with PLN Ii level only in DC (Figs. 3 and 4). Thus,blood can be used as an indicator of Ii transgene expression in
certain, but not all, cell compartments.
For some genes, the difference in transgene expression in
BM/blood and other target organs can be both quantitative
and qualitative. For example, the activities of introduced
219Expression of transgene in various organs after BM-HSC transplantationacid α-glucosidase, which is deficient in a lysosomal glycogen
storage disorder, Pompe disease, were different in blood, BM
and spleen 8 m post lentivirus-transduced HSC transplant
(van Til et al., 2010). The activities of lentivirus-encoded
α-L-iduronidase, which is deficient in another lysosomal storage
disorder, Type I mucopolysaccharidosis, were also different in
PBMC compared to other target organs, including the brain
(Visigalli et al., 2010). Accordingly, in a recent trial of human
gene therapy mediated by lentivirus, the introduced gene
function was detected directly in the target organ using
cerebrospinal fluid, in addition to blood (Biffi et al., 2013). In
our studies, introduced Ii had more enhancing effect on I-Ag7
levels in secondary immune organs, such as spleen and PLN
than it did in BM and blood (Figs. 5 and 6). The professional
APC (i.e. B cells, macrophages and DC) we studied all originate
in BM and are released into circulation, followed by maturation
in secondary immune organs, such as spleen and lymph nodes
(Gordon and Taylor, 2005; LeBien and Tedder, 2008). Ii is
required for B cell maturation (Matza et al., 2002), and Ii
level increases during the development of B cells (data not
shown, https://gexc.stanford.edu/ (Seita et al., 2012)).
GM-CSF (granulocyte-macrophage colony-stimulating factor),
the main cytokine promoting the transition of monocytes to
mature macrophages, increases Ii and not class II expression in
monocytes, but not in macrophages (Klagge et al., 1997). Ii
deficiency affects thematuration of DC carrying certain murine
class II alleles, i.e. H2b (Rovere et al., 1998). As Ii is involved in
the maturation of all three professional APC cell types, it is
perhaps not surprising that we observed Ii function at sites of
mature cells (i.e. secondary immune organs), compared to BM
and blood. The incomplete function of introduced Ii in APC from
BM and blood may be due to higher levels of cellular cystatin C
than in APC from spleen or PLN. Cystatin C is an inhibitor of
cathepsin S, the main protease in charge of Ii processing in
tissues other than thymus, and is expressed at higher levels in
immature vs. mature DC (Pierre and Mellman, 1998). Our
results suggest that during the maturation of APC, Ii function is
enhanced, in addition to the reported increase in its synthesis
(Engering et al., 1998). The phenomenon we observed likely is
not broadly generalizable, but may extend to other immune
molecules that, like Ii, interact with other developmentally
regulated proteins.
When normalized for expression differences, M98A mutant
Ii had a modestly increased ability to enhance I-Ag7 levels
compared towt Ii, confirming our in vitro data (Rinderknecht et
al., 2010). However, in these in vivo experiments, overcoming
the reduced affinity between Ii and I-Ag7 by increased wt
expression alone is also an efficient way to stabilize I-Ag7 and
may have therapeutic utility.Conclusions
We report that two transgenes (invariant chain and GFP as a
reporter gene) were both expressed using a dual-promoter
lentivirus, with the EF1a promotor driving Ii expression. After
transplantation of transduced hematopoietic stem cells (HSC),
GFP expression correlated with Ii expression in certain myeloid
cells, but not other HSC-derived cells. Ii levels in APC in bone
marrowdid not reflect Ii expression in APC in secondary immune
organs, specifically spleen and pancreatic lymph nodes (PLN); a
contributor to this result may be differences in the compositionof B220+ cells in these locations. Blood Ii levels paralleled Ii
levels in PLN only in DC. Interestingly, Ii expression had more
robust functional consequences in the more mature immune
environments, such as spleen and PLN, compared to BM and
blood cells, potentially due to other interacting proteins
expressed in these cells. Our results highlight the phenom-
ena of importance for the analysis of gene expression after
transplantation of genetically-modified HSC, particularly
evaluation of transgene expression in relevant target organs.Acknowledgments
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